WallStreetZenWallStreetZen

NASDAQ: SVRA
Savara Inc Stock

Overview
ForecastEarningsRevenueDividendOwnership
$4.75+0.02 (+0.42%)
Updated Nov 3, 2026
SVRA Price
$4.75
Fair Value Price
$0.01
Market Cap
$975.94M
52 Week Low
$3.86
52 Week High
$7.01
P/E
-8.19x
P/B
6.79x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$139.31M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.34
Operating Cash Flow
-$110M
Beta
0.9
Next Earnings
Nov 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A

SVRA Overview

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine SVRA's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

C
Value
D
Growth
C
Momentum
C
Sentiment
B
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
SVRA
Ranked#293 of 452

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Puma Biotechnology (PBYI)
$10.22A
Regeneron Pharmaceuticals (REGN)
$973.36A
Beone Medicines (ONC)
$355.00A
View Top Biotech Stocks

Be the first to know about important SVRA news, forecast changes, insider trades & much more!

SVRA News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SVRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SVRA ($4.75) is overvalued by 32,243.56% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SVRA ($4.75) is not significantly undervalued (32,243.56%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SVRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SVRA due diligence checks available for Premium users.

Valuation

SVRA fair value

Fair Value of SVRA stock based on Discounted Cash Flow (DCF)

Price
$4.75
Fair Value
$0.01
Overvalued by
32,243.56%
SVRA ($4.75) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SVRA ($4.75) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SVRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SVRA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-8.19x
Industry
15.12x
Market
44.51x

SVRA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
6.79x
Industry
5.16x
SVRA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SVRA's financial health

Profit margin

Revenue
$0.0
Net Income
-$40.2M
Profit Margin
0%
SVRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$192.1M
Liabilities
$48.5M
Debt to equity
0.34
SVRA's short-term assets ($178.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SVRA's short-term assets ($178.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SVRA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SVRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$29.7M
Investing
$32.6M
Financing
$189.0k
SVRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SVRA vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
SVRAD$975.94M+0.42%-8.19x6.79x
IMTXD$967.08M+0.21%-3.82x2.09x
LTGOD$965.98M+7.85%N/A-3.50x
ORICD$994.03M+5.73%-7.27x2.61x
MLTXF$995.75M+2.01%-3.05x2.33x
View Top Biotech Stocks

Savara Stock FAQ

What is Savara's quote symbol?

(NASDAQ: SVRA) Savara trades on the NASDAQ under the ticker symbol SVRA. Savara stock quotes can also be displayed as NASDAQ: SVRA.

If you're new to stock investing, here's how to buy Savara stock.

What is the 52 week high and low for Savara (NASDAQ: SVRA)?

(NASDAQ: SVRA) Savara's 52-week high was $7.01, and its 52-week low was $3.86. It is currently -32.19% from its 52-week high and 23.06% from its 52-week low.

How much is Savara stock worth today?

(NASDAQ: SVRA) Savara currently has 205,460,015 outstanding shares. With Savara stock trading at $4.75 per share, the total value of Savara stock (market capitalization) is $975.94M.

Savara stock was originally listed at a price of $8.76 in Apr 28, 2017. If you had invested in Savara stock at $8.76, your return over the last 9 years would have been -45.78%, for an annualized return of -6.57% (not including any dividends or dividend reinvestments).

How much is Savara's stock price per share?

(NASDAQ: SVRA) Savara stock price per share is $4.75 today (as of Nov 3, 2026).

What is Savara's Market Cap?

(NASDAQ: SVRA) Savara's market cap is $975.94M, as of Nov 4, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Savara's market cap is calculated by multiplying SVRA's current stock price of $4.75 by SVRA's total outstanding shares of 205,460,015.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.